{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:24:59Z","timestamp":1773084299650,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["faseb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The worldwide incidence of rabies and the inability of currently used vaccination strategies to provide highly potent and cost\u2010effective therapy indicate the need for an improved rabies vaccine. Thus, DNA vaccine based on lysosome\u2010targeted gly\u2010coprotein of the rabies virus was evaluated in BALB\/c mice. It imparted partial protection (60%) against challenge with 20 LD\n                    <jats:sub>50<\/jats:sub>\n                    of the challenge virus standard (CVS) strain of rabies virus. To improve the outcome of vaccination, to ultimately enhance the immune response, we investigated different routes for DNA vaccine delivery, varied doses of DNA, and the influence of adjuvant supplementation. The highest immune response pertaining to IgG antibody titer, with a predominantly IgG1\/IgG2a subclass distribution, effective cellular immunity, and a high level of rabies virus neutralizing antibodies (RVNAs) was attained by the optimized DNA vaccine formulation comprising intramuscular administration of 100 \u03bcg of DNA vaccine supplemented with Emulsi\u2010gen\u00ae\u2010D. In preexposure prophylaxis, a 3\u2010dose regimen of this formulation generated a high RVNA titer (32 IU\/ml) and conferred complete protection against challenge with 20 LD\n                    <jats:sub>50<\/jats:sub>\n                    of CVS. For postexposure efficacy analysis, rabies was experimentally induced with 50 LD\n                    <jats:sub>50<\/jats:sub>\n                    of CVS. Subsequent therapy with 5 doses of the formulation completely prevented rabies in BALB\/c mice, which maintained protective RVNA titers of 4 IU\/ml. The World Health Organization recommended rabies protective titer threshold is 0.5 IU\/ml. Thus, this optimized DNA vaccine formulation provides an avenue for preventing and controlling rabies.\u2014Kaur, M., Saxena, A., Rai, A., and Bhatnagar, R. Rabies DNA vaccine encoding lyso\u2010some\u2010targeted glycoprotein supplemented with Emulsi\u2010gen\u2010D confers complete protection in preexposure and postexposure studies in BALB\/c mice.\n                    <jats:italic>FASEB J<\/jats:italic>\n                    . 24, 173\u2013183 (2010).\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fasebj.org\">www.fasebj.org<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1096\/fj.09-138644","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T21:50:35Z","timestamp":1252533035000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rabies DNA vaccine encoding lysosome\u2010targeted glycoprotein supplemented with Emulsigen\u2010D confers complete protection in preexposure and postexposure studies in BALB\/c mice"],"prefix":"10.1096","volume":"24","author":[{"given":"Manpreet","family":"Kaur","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology and Genetic Engineering School of Biotechnology Jawaharlal Nehru University New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Saxena","sequence":"additional","affiliation":[{"name":"National Biotechnology Center Indian Veterinary Research Institute Izatnagar India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Rai","sequence":"additional","affiliation":[{"name":"National Biotechnology Center Indian Veterinary Research Institute Izatnagar India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and Genetic Engineering School of Biotechnology Jawaharlal Nehru University New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,9]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"425","volume":"82","author":"World Health Organization","year":"2007","journal-title":"Wkly. Epidemiol. Rec."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intrader-mally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine","volume":"23","author":"Beran J.","year":"2005","journal-title":"Vaccine"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.128"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00147-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5388.476"},{"key":"e_1_2_7_9_1","first-page":"1","article-title":"Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy","volume":"4","author":"Kim N.","year":"2006","journal-title":"Clin. Mol. Allergy"},{"key":"e_1_2_7_10_1","first-page":"5845","article-title":"Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma","volume":"62","author":"Timmerman J. M.","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.05.007"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.37.3.93"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.46.3.241"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.120"},{"key":"e_1_2_7_15_1","first-page":"181","volume-title":"Laboratory Techniques in Rabies","author":"Smith J. S.","year":"1996"},{"key":"e_1_2_7_16_1","first-page":"2782","article-title":"Safety and immunogenicity of DNA vaccine encoding carcino-embryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients","volume":"8","author":"Conry R. M.","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00068-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1996.d01-718.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.4049\/jimmunol.158.10.4529","article-title":"Differential dependence on target site tissue for gene gun and intramuscular DNA immunization","volume":"158","author":"Torres C. A.","year":"1997","journal-title":"J. Immunol."},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.4049\/jimmunol.163.9.4721","article-title":"In vivo priming by DNA injection occurs predominantly by antigen transfer","volume":"163","author":"Corr M.","year":"1999","journal-title":"J. Immunol."},{"key":"e_1_2_7_21_1","first-page":"216","article-title":"The immunology of cutaneous DNA immunization","author":"Turing T.","year":"1999","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00275-5"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(03)00024-5"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/10430340360464732"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14712598.4.6.889","article-title":"Particle-mediated DNA vaccine delivery to the skin","volume":"4","author":"Hynes J. R.","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00247-9"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.vaccine.2005.09.016","article-title":"Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions","volume":"24","author":"Bahloul C.","year":"2005","journal-title":"Vaccine"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)88325-9"},{"key":"e_1_2_7_29_1","first-page":"221","article-title":"Rabies DNA vaccination by the intranasal route in dogs","volume":"125","author":"Tesoro C. E.","year":"2006","journal-title":"Dev. Biol. (Basel)"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.24.11478"},{"key":"e_1_2_7_31_1","volume-title":"Bio-Rad Technical Note 2726","author":"Conn A."},{"key":"e_1_2_7_32_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.0105-2896.2004.00140.x","article-title":"Strategies for improved formulation and delivery of DNA vaccines to veterinary target species","volume":"199","author":"Van Drunen Little-van den Hurk S.","year":"2004","journal-title":"Immunol. Rev."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602019"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1128\/jvi.71.1.169-178.1997","article-title":"Improvement ofhepatitis B virus DNAvaccines by plasmids co-expressing hepatitis B surface antigen and interleu-kin-2","volume":"71","author":"Chow Y. H.","year":"1997","journal-title":"J. Virol."},{"key":"e_1_2_7_35_1","first-page":"251","article-title":"Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D","volume":"50","author":"Li W. R.","year":"2006","journal-title":"Acta Virol."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.015"},{"key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.158.8.3635","article-title":"Contribution of CpG motifs to the immunogenicity of DNA vaccines","volume":"158","author":"Klinman D. M.","year":"1997","journal-title":"J. Immunol."},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00151-6"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00504-8"},{"key":"e_1_2_7_40_1","volume-title":"AASV Swine Information CD-ROM Catalog 221\u2013228","author":"Lin B. C.","year":"2006"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.08.040190.001511"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(90)90015-K"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.20.10540-10545.2002"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1994.1105"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00568-1"},{"key":"e_1_2_7_46_1","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1016\/j.vaccine.2008.09.083","article-title":"Efficient post-exposure prophylaxis against rabies by applying a four-dose DNA vaccine intra-nasally","volume":"26","author":"Cruza E. T.","year":"2008","journal-title":"Vaccine"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00328-4"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.051"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00297-4"}],"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.09-138644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1096\/fj.09-138644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.09-138644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T20:51:00Z","timestamp":1761684660000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fj.09-138644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1096\/fj.09-138644"],"URL":"https:\/\/doi.org\/10.1096\/fj.09-138644","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"value":"0892-6638","type":"print"},{"value":"1530-6860","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,9]]},"assertion":[{"value":"2009-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}